Diabetes Metab J.  2024 Jan;48(1):55-58. 10.4093/dmj.2023.0442.

Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus

• Roh E

• KMID: 2551262
• DOI: http://doi.org/10.4093/dmj.2023.0442

Reference

1. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–81.

2. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–74.

3. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002; 106:1943–8.

4. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018; 137:1571–82.

5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:111–88.

6. Yang YS, Kim HL, Kim SH, Moon MK; Committee of Clinical Practice Guideline, Korean Diabetes Association; Clinical Practice Guideline Committee, Korean Society of Lipid and Atherosclerosis. Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. J Lipid Atheroscler. 2023; 12:12–22.

7. Lee YH, Hong N, Lee CJ, Park SH, Lee BW, Cha BS, et al. Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. Sci Rep. 2018; 8:11925.

8. Hong N, Lee YH, Tsujita K, Gonzalez JA, Kramer CM, Kovarnik T, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis. Endocrinol Metab (Seoul). 2018; 33:219–27.

9. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181–92.

10. Han JH, Joung KH, Lee JC, Kim OS, Choung S, Kim JM, et al. Comparative efficacy of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus. Diabetes Metab J. 2024; 48:112–21.

11. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATPbinding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006; 49:1008–16.

12. Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012; 30:61–74.

13. Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011; 13:615–28.

14. Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2019; 34:916–25.

15. Chang E, Kim L, Choi JM, Park SE, Rhee EJ, Lee WY, et al. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015; 64:633–41.

16. Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016; 10:306–13.

17. Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018; 60:229–39.

18. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multi-center randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015; 66:495–507.

19. Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022; 7:265.

20. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment. Int J Mol Sci. 2022; 23:3418.